TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32580838

Group type: EXPERIMENTAL
Intervention: Programmed intermittent epidural bolus (PIEB) plus patient-controlled epidural analgesia (PCEA) at 30-minute intervals with a pulse dose of 5 mL (Group A)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Programmed intermittent epidural bolus (PIEB) plus patient-controlled epidural analgesia (PCEA) at 60-minute intervals with a pulse dose of 10 mL (Group B)
Number of subjects: 170
Study: 34726317

Group type: COMPARATOR
Intervention: Continuous low-energy diet (CLED) - 8 weeks/56 days of daily Optifast 820 kcal (3430 kJ) diet
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Intermittent low-energy diet (ILED) - 2 days of Optifast and 5 days of a Mediterranean diet/week for 28 weeks
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Both groups (ILED and CLED)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Intermittent low-energy diet (ILED)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Continuous low-energy diet (CLED)
Number of subjects: 79
Study: 32803265

Group type: EXPERIMENTAL
Intervention: Dry/damp followed by wet cleaning
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Wet cleaning followed by dry/damp cleaning
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Dry/damp and wet cleaning applied the same day
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Dry/damp and wet cleaning (combined)
Number of subjects: 48
Study: 36162373

Group type: EXPERIMENTAL
Intervention: Calcium alginate dressings with ZnO nanoparticles (G1; n = 16)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Calcium alginate dressings without ZnO nanoparticles (G2; n = 10)
Number of subjects: 26
Study: 34720688

Group type: EXPERIMENTAL
Intervention: Complex social accountability intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study: 34170842

Group type: EXPERIMENTAL
Intervention: Vascular closure devices (VCDs)
Number of subjects: 694

Group type: COMPARATOR
Intervention: No vascular closure devices (no VCD)
Number of subjects: 694
Study: 34574492

Group type: EXPERIMENTAL
Intervention: Physical Activity Programs (PA)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Men compared to women
Number of subjects: 307

Group type: COMPARATOR
Intervention: People with at least primary education compared to those with no education
Number of subjects: 307
Study: 34706835

Group type: EXPERIMENTAL
Intervention: Retention group (gubernaculum preserving laparoscopic orchiopexy)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Cutting group (gubernaculum cutting laparoscopic orchiopexy)
Number of subjects: 120
Study: 32374371

Group type: EXPERIMENTAL
Intervention: Laparoscopic total mesorectal excision by upper quartile-scoring surgeons
Number of subjects: 176

Group type: COMPARATOR
Intervention: Laparoscopic total mesorectal excision by lower quartile-scoring surgeons
Number of subjects: 176
Study: 34460933

Group type: EXPERIMENTAL
Intervention: GOP infusion (n = 14)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Very Low-Calorie Diet (VLCD) (n = 22)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Roux-en-Y Gastric Bypass (RYGB) (n = 21)
Number of subjects: 25

Group type: COMPARATOR
Intervention: 0.9% saline control (n = 11)
Number of subjects: 25
Study: 34217955

Group type: EXPERIMENTAL
Intervention: Guided graded exercise self-help (GES)
Number of subjects: 0
Study: 36008202

Group type: EXPERIMENTAL
Intervention: Continuous intra-arterial monitoring
Number of subjects: 242

Group type: COMPARATOR
Intervention: Intermittent oscillometric monitoring
Number of subjects: 242
Study: 34862226

Group type: EXPERIMENTAL
Intervention: Screening for clinical trial participation
Number of subjects: 213
Study: 32078917

Group type: EXPERIMENTAL
Intervention: Working Memory Training (WMT), 5-week adaptive program
Number of subjects: 76

Group type: COMPARATOR
Intervention: Passive waiting-list control group (CG)
Number of subjects: 76
Study: 34583841

Group type: EXPERIMENTAL
Intervention: Long-term psychodynamic psychotherapy (LPP)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Solution-focused therapy (SFT)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Short-term psychodynamic psychotherapy (SPP)
Number of subjects: 326
Study: 32294346

Group type: EXPERIMENTAL
Intervention: SEP‐363856 (50 mg or 75 mg)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 245
Study: 33919630

Group type: EXPERIMENTAL
Intervention: Mediterranean dietary pattern (MDP) adherence
Number of subjects: 175

Group type: COMPARATOR
Intervention: Breakfast quality
Number of subjects: 175

Group type: COMPARATOR
Intervention: Physical activity adjustment
Number of subjects: 175
Study: 32076003

Group type: EXPERIMENTAL
Intervention: Social network intervention (random assignment into small groups at an introduction event two months prior to university)
Number of subjects: 0
Study: 32024793

Group type: EXPERIMENTAL
Intervention: PARTNER model of service delivery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 35349757

Group type: EXPERIMENTAL
Intervention: Ganciclovir treatment
Number of subjects: 217

Group type: COMPARATOR
Intervention: No ganciclovir treatment (Control)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Nonsurvivors (Control)
Number of subjects: 217
Study: 33340245

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg
Number of subjects: 86

Group type: COMPARATOR
Intervention: Gabapentin 300 mg
Number of subjects: 86
Study: 32289471

Group type: EXPERIMENTAL
Intervention: Diabetes coping skills training (DCST) intervention plus diabetes education
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diabetes education alone
Number of subjects: 0
Study: 35739147

Group type: COMPARATOR
Intervention: Intravitreal aflibercept (IVA) monotherapy
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVA) + subthreshold laser (SL) combination therapy
Number of subjects: 51
Study: 32616406

Group type: EXPERIMENTAL
Intervention: Urodynamics (UDS)
Number of subjects: 820

Group type: COMPARATOR
Intervention: Routine Care (RC)
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 820
Study: 32686217

Group type: EXPERIMENTAL
Intervention: Sodium lauryl sulphate irritation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tape stripping
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ultraviolet radiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tested preparation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control, undamaged site
Number of subjects: 0
Study: 33081817

Group type: EXPERIMENTAL
Intervention: Combination therapy with macrolide azithromycin and hydroxychloroquine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35381930

Group type: EXPERIMENTAL
Intervention: Neuroendoscopic surgery (NES)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Extraventricular drainage (EVD)
Number of subjects: 83
Study: 34322703

Group type: EXPERIMENTAL
Intervention: Venetoclax plus low-dose cytarabine
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo plus low-dose cytarabine
Number of subjects: 27
Study: 32614227

Group type: EXPERIMENTAL
Intervention: Sociometric Badge (SB) condition (n = 75 dyads)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Standard recording device condition (n = 78 dyads)
Number of subjects: 306
Study: 35865301

Group type: EXPERIMENTAL
Intervention: MA VR scene + TBS
Number of subjects: 45

Group type: COMPARATOR
Intervention: MA VR scene + sham TBS
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: neutral VR scene + TBS
Number of subjects: 45
Study: 32981091

Group type: EXPERIMENTAL
Intervention: Helping Mothers Survive Bleeding after Birth training
Number of subjects: 58000
Study: 33066061

Group type: EXPERIMENTAL
Intervention: Pilates method with therapeutic exercise
Number of subjects: 25

Group type: COMPARATOR
Intervention: Therapeutic exercise
Number of subjects: 25
Study: 36200820

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Mobile Compression Pumps
Number of subjects: 80
Study: 34794061

Group type: EXPERIMENTAL
Intervention: Opioid Craving Visual Analog Scale (OC-VAS)
Number of subjects: 487
Study: 34978954

Group type: EXPERIMENTAL
Intervention: Spinal stabilization exercises (SSE)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Home exercise program (control)
Number of subjects: 10
Study: 33798287

Group type: EXPERIMENTAL
Intervention: Misoprostol treatment
Number of subjects: 184

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 184
Study: 33268629

Group type: EXPERIMENTAL
Intervention: Sonic wave vibration (SWV) for 10 minutes per day, 5 days a week for 8 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sonic wave vibration (SWV)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 32496892

Group type: EXPERIMENTAL
Intervention: Benefit-finding intervention
Number of subjects: 68

Group type: COMPARATOR
Intervention: Routine health education (Control)
Number of subjects: 68
Study: 32266412

Group type: EXPERIMENTAL
Intervention: Attention tests including the Digit Span Test (DST)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Attention tests including the Symbol Digit Modalities Test (SDMT)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Attention tests including the Paced Auditory Serial Addition Test (PASAT)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Digit Cancellation Test (D-CAT1 and D-CAT2)
Number of subjects: 89
Study: 35255426

Group type: EXPERIMENTAL
Intervention: Cyanidin‐ and delphinidin‐rich extract (CDRE) providing 320.4 mg of anthocyanins (90% cyanidin and delphinidin)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 34663236

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced mammography (CEM)
Number of subjects: 440

Group type: COMPARATOR
Intervention: No further imaging (Control)
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: CEM
Number of subjects: 440
Study: 36183049

Group type: EXPERIMENTAL
Intervention: IP-SSCV
Number of subjects: 250

Group type: COMPARATOR
Intervention: OOP-IJV
Number of subjects: 250
Study: 33738617

Group type: EXPERIMENTAL
Intervention: Minodronate
Number of subjects: 3247

Group type: COMPARATOR
Intervention: Raloxifene
Number of subjects: 3247
Study: 32416821

Group type: COMPARATOR
Intervention: 3,000 IU/kg vitamin D3 (control)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 3,000 IU/kg 25-hydroxyvitamin D3 (T1)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 9,000 IU/kg 25-hydroxyvitamin D3 (T2)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 3,000 IU/kg vitamin D3 (T3)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 9,000 IU/kg vitamin D3 (T4)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 3,000 IU/kg vitamin D2 (T5)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 9,000 IU/kg vitamin D2 (T6)
Number of subjects: 42
Study: 36322173

Group type: EXPERIMENTAL
Intervention: Minimally invasive total hysterectomy and sacrocolpopexy with lightweight mesh
Number of subjects: 106
Study: 33958495

Group type: EXPERIMENTAL
Intervention: Vibroacoustic therapy using the VITAFON-2 apparatus
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo apparatus
Number of subjects: 60
Study: 33154056

Group type: EXPERIMENTAL
Intervention: Human papillomavirus-based screening (either GP-based or self-sampling)
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Standard care (cervical cytology sample at GP or gynaecologist)
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Self-sampling
Number of subjects: 10000
Study: 35737102

Group type: EXPERIMENTAL
Intervention: Group iSLN: bilateral perineural injection with 4 mg dexamethasone around the internal branch of superior laryngeal nerve
Number of subjects: 161

Group type: COMPARATOR
Intervention: Group Spray: 4 mg dexamethasone sprayed on the vocal cord
Number of subjects: 161
Study: 33258032

Group type: EXPERIMENTAL
Intervention: Stent treatment
Number of subjects: 43

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 43
Study: 33036471

Group type: EXPERIMENTAL
Intervention: Extra-virgin olive oil (EVO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corn oil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Animal fat
Number of subjects: 0
Study: 35074322

Group type: EXPERIMENTAL
Intervention: PERI‐OP intervention
Number of subjects: 137

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 137
Study: 35219356

Group type: EXPERIMENTAL
Intervention: Early treatment with fluvoxamine
Number of subjects: 0
Study: 33261700

Group type: EXPERIMENTAL
Intervention: tCBT + TAU
Number of subjects: 231

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 231
Study: 34896916

Group type: EXPERIMENTAL
Intervention: Interactive educational app about VTE and anticoagulation
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 56
Study: 34467742

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM)
Number of subjects: 43
Study: 32962981

Group type: EXPERIMENTAL
Intervention: Moderate/severe DKA
Number of subjects: 758

Group type: EXPERIMENTAL
Intervention: Moderate/severe DKA in newly diagnosed patients
Number of subjects: 758

Group type: EXPERIMENTAL
Intervention: Repeated DKA exposure in previously diagnosed patients
Number of subjects: 758

Group type: EXPERIMENTAL
Intervention: Higher HbA1c in previously diagnosed patients
Number of subjects: 758
Study: 35440521

Group type: EXPERIMENTAL
Intervention: ACB with magnesium and bupivacaine (n=56)
Number of subjects: 119

Group type: COMPARATOR
Intervention: ACB with bupivacaine only (n=63)
Number of subjects: 119
Study: 35960163

Group type: EXPERIMENTAL
Intervention: High cardiorespiratory fitness
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: High or moderate cardiorespiratory fitness
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity
Number of subjects: 185
Study: 35485333

Group type: EXPERIMENTAL
Intervention: Rilpivirine plus darunavir/cobicistat (25 mg rilpivirine plus 800/150 mg darunavir/cobicistat once daily)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard three-drug therapy (late switch group)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Rilpivirine plus darunavir/cobicistat
Number of subjects: 160
Study: 35764016

Group type: EXPERIMENTAL
Intervention: Predictive model for remission probability of LN
Number of subjects: 301
Study: 33691730

Group type: EXPERIMENTAL
Intervention: Diuretic (furosemide)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Control
Number of subjects: 166
Study: 32178705

Group type: EXPERIMENTAL
Intervention: Yoga intervention (24-week program, 90 min once a week, at least 2 at-home sessions of 15 min each)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 26
Study: 36459409

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (exercise, nutrition, and psychosocial programs) once a week for 8 weeks
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 69
Study: 33773391

Group type: EXPERIMENTAL
Intervention: Cimicoxib
Number of subjects: 42

Group type: COMPARATOR
Intervention: Tramadol
Number of subjects: 42
Study: 33791916

Group type: EXPERIMENTAL
Intervention: Spironolactone therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33646835

Group type: EXPERIMENTAL
Intervention: Oxford/AstraZeneca vaccine (ChAdOx1 nCoV‐19)
Number of subjects: 0
Study: 34618716

Group type: EXPERIMENTAL
Intervention: Prolonged Grief Disorder (PGD)
Number of subjects: 195

Group type: COMPARATOR
Intervention: No PGD
Number of subjects: 195
Study: 33883174

Group type: EXPERIMENTAL
Intervention: Allogenic FMT (healthy obese donor)
Number of subjects: 24
Study: 36136951

Group type: EXPERIMENTAL
Intervention: Bifiform Kids (2 chewable tablets twice per day for 21 days)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (no probiotics)
Number of subjects: 92
Study: 34116393

Group type: EXPERIMENTAL
Intervention: Magnesium treatment for 12 weeks
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo arm
Number of subjects: 250
Study: 33009185

Group type: EXPERIMENTAL
Intervention: Rectus sheath block (RSB) with 2 mg/kg of levobupivacaine
Number of subjects: 97

Group type: COMPARATOR
Intervention: Spinal anaesthesia with 12.5 mg hyperbaric bupivacaine and 0.5 mg diamorphine
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 97
Study: 32817406

Group type: EXPERIMENTAL
Intervention: Single high neurofilament light chain (NfL) measure at baseline (BL)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: NfLlong measured over 24 months
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: NfLlong combined with clinical and MRI measures
Number of subjects: 274
Study: 36057030

Group type: EXPERIMENTAL
Intervention: Rebaudioside A (3 g)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 33832143

Group type: EXPERIMENTAL
Intervention: Improved simulation tool training
Number of subjects: 120

Group type: COMPARATOR
Intervention: Traditional method training
Number of subjects: 120
Study: 34339618

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) infusion
Number of subjects: 30

Group type: COMPARATOR
Intervention: Clonidine (CLON) infusion
Number of subjects: 30
Study: 32632246

Group type: EXPERIMENTAL
Intervention: Slaughter equation for body fatness assessment
Number of subjects: 69746
Study: 36171022

Group type: EXPERIMENTAL
Intervention: Strengthening Care for Children (SC4C) intervention
Number of subjects: 21
Study: 32461053

Group type: EXPERIMENTAL
Intervention: Topical ivermectin (0.1%)‐metronidazole (1%) gel treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 60
Study: 32633244

Group type: EXPERIMENTAL
Intervention: Manosar® (2 g of d-mannose + 140 mg of proanthocyanidins)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Isolated PAC (240 mg of continuous-release proanthocyanidins)
Number of subjects: 283
Study: 34562471

Group type: EXPERIMENTAL
Intervention: Powered endoscopic debridement (PED) system
Number of subjects: 30
Study: 36166391

Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual procedure
Number of subjects: 40
Study: 33592131

Group type: EXPERIMENTAL
Intervention: lipo-PGE1
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control
Number of subjects: 89
Study: 35042152

Group type: EXPERIMENTAL
Intervention: Alectinib 600 mg twice daily
Number of subjects: 119

Group type: COMPARATOR
Intervention: Chemotherapy (pemetrexed 500 mg/m2 or docetaxel 75 mg/m2, every 3 weeks)
Number of subjects: 119
Study: 33217335

Group type: EXPERIMENTAL
Intervention: Empagliflozin (10 mg and 25 mg)
Number of subjects: 7020

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7020
Study: 34233727

Group type: COMPARATOR
Intervention: Maintenance therapy with TNFi plus MTX
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Switched therapy with tacrolimus (TAC) plus MTX
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Switched therapy with TAC plus MTX
Number of subjects: 114
Study: 34414521

Group type: EXPERIMENTAL
Intervention: MISTms alone
Number of subjects: 36

Group type: COMPARATOR
Intervention: MISTms combined (with deproteinized bovine bone mineral and collagen membrane)
Number of subjects: 36

Group type: COMPARATOR
Intervention: MISTms combined
Number of subjects: 36
Study: 34009242

Group type: EXPERIMENTAL
Intervention: Motor exercise intervention (n=24), 12-week exercise training program
Number of subjects: 47

Group type: COMPARATOR
Intervention: Waiting control group (n=23), abstaining from any exercise program
Number of subjects: 47
Study: 32586295

Group type: EXPERIMENTAL
Intervention: Work-related walking (low amount)
Number of subjects: 1080

Group type: EXPERIMENTAL
Intervention: Work-related walking (high amount)
Number of subjects: 1080

Group type: COMPARATOR
Intervention: Work-related physical activity (any intensity) for professionals
Number of subjects: 1080

Group type: COMPARATOR
Intervention: Work-related physical activity (any intensity) for sales and service workers
Number of subjects: 1080
Study: 34849920

Group type: EXPERIMENTAL
Intervention: In vitro maturation (IVM) without stimulation
Number of subjects: 351

Group type: COMPARATOR
Intervention: Standard in vitro fertilization (IVF) with flexible GnRH antagonist protocol and hCG as ovulatory trigger
Number of subjects: 351

Group type: COMPARATOR
Intervention: Standard in vitro fertilization (IVF)
Number of subjects: 351
Study: 32154591

Group type: EXPERIMENTAL
Intervention: Mendelian randomisation (MR)
Number of subjects: 0
Study: 34914094

Group type: EXPERIMENTAL
Intervention: Stepping Stones and Creating Futures (SSCF) intervention
Number of subjects: 0
Study: 35472058

Group type: EXPERIMENTAL
Intervention: Circle of Security-parenting (COS-P)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 186
Study: 33788837

Group type: EXPERIMENTAL
Intervention: Direct laryngoscopy (DL)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Box barrier with direct laryngoscopy (BoxDL)
Number of subjects: 18
Study: 36868916

Group type: EXPERIMENTAL
Intervention: AF ablation
Number of subjects: 31

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 31
Study: 33655380

Group type: EXPERIMENTAL
Intervention: IV golimumab 2 mg/kg at Weeks 0, 4, then every 8 weeks through Week 52
Number of subjects: 480

Group type: COMPARATOR
Intervention: Placebo at Weeks 0, 4, then every 8 weeks, crossover to IV golimumab at Weeks 24, 28, then every 8 weeks through Week 52
Number of subjects: 480
Study: 35332807

Group type: EXPERIMENTAL
Intervention: eptinezumab 100 mg
Number of subjects: 1072

Group type: EXPERIMENTAL
Intervention: eptinezumab 300 mg
Number of subjects: 1072

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1072
Study: 34847938

Group type: EXPERIMENTAL
Intervention: Training on maternal depression (one-day training)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Supportive supervision (for half of the experimental group)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no training or supervision)
Number of subjects: 12
Study: 32658013

Group type: EXPERIMENTAL
Intervention: Tissue CMV PCR positivity
Number of subjects: 76

Group type: COMPARATOR
Intervention: Histopathological examinations (HE/IHC)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Blood CMV viral load (BVL)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Tissue viral load (TVL)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Tissue CMV DNA
Number of subjects: 76